Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Next Science Ltd ( (AU:NXS) ) has issued an update.
Next Science has called an extraordinary general meeting for 28 January 2026 to seek shareholder approval for an initial capital return of about A$0.145 per share, totalling roughly A$42.5 million, followed by the company’s removal from the ASX official list. Subject to shareholders endorsing the capital return and delisting, the board expects to convene a further meeting in February 2026 to propose a voluntary winding up and appointment of a liquidator, while CEO and managing director I.V. Hall and CFO Marc Zimmerman will step down on 31 December 2025 after the completion of the asset sale to OSARTIS, marking a decisive transition towards winding down the listed entity and returning value to shareholders.
The most recent analyst rating on (AU:NXS) stock is a Hold with a A$0.14 price target. To see the full list of analyst forecasts on Next Science Ltd stock, see the AU:NXS Stock Forecast page.
More about Next Science Ltd
Next Science Limited is an ASX-listed medical technology company that has historically focused on developing and commercialising anti-infective products, particularly targeting biofilm-based infections. In September 2025, the company completed the sale of substantially all of its assets and those of its wholly owned subsidiaries to OSARTIS GmbH, a Demetra Holding S.p.A subsidiary, and has since applied to be removed from the ASX official list, signalling an exit from its previous operating structure and public market listing.
Average Trading Volume: 235,884
Technical Sentiment Signal: Sell
Current Market Cap: A$40.97M
Learn more about NXS stock on TipRanks’ Stock Analysis page.